Method and kit for distinguishing between prostate carcinoma and benign prostatic hyperplasia
US-2015260720-A1 · Sep 17, 2015 · US
Monoclonal antibody that specifically binds to sugar chain in which terminal sialic acid residue is bonded to galactose by alpha 2,3 bond, and measurement method for sugar chain in which terminal sialic acid residue is bonded to galactose by alpha 2,3 bond
US11987643B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11987643-B2 |
| Application number | US-202117918042-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 18, 2021 |
| Priority date | Mar 18, 2021 |
| Publication date | May 21, 2024 |
| Grant date | May 21, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A monoclonal antibody or an antibody fragment thereof is provided, in which the monoclonal antibody or the antibody fragment thereof specifically binds to a sugar chain in which a terminal sialic acid residue is bonded to galactose by an α2,3 bond, and is not dissociated from the sugar chain after the binding to the sugar chain in which the terminal sialic acid residue is bonded to the galactose by the α2,3 bond.α2,3
First claim
Opening claim text (preview).
The invention claimed is: 1. A monoclonal antibody or the antibody fragment thereof, wherein an amino acid sequence of a complementarity-determining region (CDR) 1 (CDR1) of a heavy chain variable region (VH) of the antibody or the antibody fragment thereof comprises the amino acid sequence set forth in SEQ ID NO:1, an amino acid sequence of CDR2 of the VH comprises the amino acid sequence set forth in SEQ ID NO:2, an amino acid sequence of CDR3 of the VH comprises the amino acid sequence set forth in SEQ ID NO:3, an amino acid sequence of CDR1 of a light chain variable region (VL) comprises the amino acid sequence set forth in SEQ ID NO:4, an amino acid sequence of CDR2 of the VL comprises the amino acid sequence set forth in SEQ ID NO:5, and an amino acid sequence of CDR3 of the VL comprises the amino acid sequence set forth in SEQ ID NO:6. 2. The monoclonal antibody or the antibody fragment thereof of claim 1 , wherein an amino acid sequence of the VH of the antibody or the antibody fragment thereof comprises the amino acid sequence set forth in SEQ ID NO:13, and an amino acid sequence of the VL comprises the amino acid sequence set forth in SEQ ID NO:14. 3. A monoclonal antibody or the antibody fragment thereof, wherein an amino acid sequence of CDR1 of the VH of the antibody or the antibody fragment thereof comprises the amino acid sequence set forth in SEQ ID NO:7, an amino acid sequence of CDR2 of the VH comprises the amino acid sequence set forth in SEQ ID NO:8, an amino acid sequence of CDR3 of the VH comprises the amino acid sequence set forth in SEQ ID NO:9, an amino acid sequence of CDR1 of the VL comprises the amino acid sequence set forth in SEQ ID NO:10, an amino acid sequence of CDR2 of the VL comprises the amino acid sequence set forth in SEQ ID NO:11, and an amino acid sequence of CDR3 of the VL comprises the amino acid sequence set forth in SEQ ID NO:12. 4. The monoclonal antibody or the antibody fragment thereof of claim 3 , wherein an amino acid sequence of the VH of the antibody or the antibody fragment thereof comprises the amino acid sequence set forth in SEQ ID NO:15 and an amino acid sequence of the VL comprises the amino acid sequence set forth in SEQ ID NO:16.
Assignees
Inventors
Classifications
- C07K16/44Primary
against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title
involving blood sugars, e.g. galactose · CPC title
Complementarity determining region [CDR] · CPC title
Reproductive system, e.g. ovaria, uterus, testes, prostate · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11987643B2 cover?
- A monoclonal antibody or an antibody fragment thereof is provided, in which the monoclonal antibody or the antibody fragment thereof specifically binds to a sugar chain in which a terminal sialic acid residue is bonded to galactose by an α2,3 bond, and is not dissociated from the sugar chain after the binding to the sugar chain in which the terminal sialic acid residue is bonded to the galactos…
- Who is the assignee on this patent?
- Univ Hirosaki, System Instruments Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/44. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).